First Tracks Biotherapeutics, Inc. (TRAX) vs UroGen Pharma Ltd. (URGN)
First Tracks Biotherapeutics, Inc. and UroGen Pharma Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — TRAX vs URGN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| First Tracks Biotherapeutics, Inc. (TRAX) | UroGen Pharma Ltd. (URGN) | |
|---|---|---|
| Market cap | $0.6B | $1.4B |
| Revenue (latest FY) | — | $109.79M |
| Net income (latest FY) | $-163.71M | $-153.49M |
| Revenue growth (5y CAGR) | — | 56.2% |
| Net margin | — | -139.8% |
| Return on equity | -41.8% | 145.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Performance — TRAX vs URGN
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| First Tracks Biotherapeutics, Inc. (TRAX) | UroGen Pharma Ltd. (URGN) | |
|---|---|---|
| 1-year return | — | 106.6% |
| 3-year return | — | 173.5% |
| 5-year return | — | 85.4% |
| 10-year return | — | — |
| 52-week range | $14.72–$26.80 | $6.92–$32.37 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full TRAX vs URGN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open TRAX's full financials → Open URGN's full financials →More comparisons
Frequently asked questions
Which is bigger, TRAX or URGN?
UroGen Pharma Ltd. is larger by market capitalization — $1.4B versus $0.6B.
Which grows faster, TRAX or URGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.